Efficacy, Safety, and Tolerability of RBP-7000 Once-Monthly Risperidone for the Treatment of Acute Schizophrenia-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Efficacy, Safety, and Tolerability of RBP-7000 Once-Monthly Risperidone for the Treatment of Acute Schizophrenia

Published:2016-04 Issue:2 Volume:36 Page:130-140
ISSN:0271-0749
Container-title:Journal of Clinical Psychopharmacology
language:en
Short-container-title:

Author:

Nasser Azmi F.,Henderson David C.,Fava Maurizio,Fudala Paul J.,Twumasi-Ankrah Philip,Kouassi Alex,Heidbreder Christian

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Pharmacology (medical),Psychiatry and Mental health

Reference39 articles.

1. Schizophrenia: manifestations, incidence and course in different cultures. A World Health Organization ten-country study.;Jablensky;Psychol Med Monogr Suppl,1992

2. Catching up on schizophrenia: natural history and neurobiology.;Lewis;Neuron,2000

3. Humanistic burden in schizophrenia: a literature review.;Millier;J Psychiatr Res,2014

4. Factors influencing relapse in the long-term course of schizophrenia.;Ayuso-Gutierrez;Schizophr Res,1997

5. Compliance with medication regimens for mental and physical disorders.;Cramer;Psychiatr Serv,1998

Cited by 38 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. An overview of the currently available and emerging long-acting formulations of risperidone for schizophrenia and bipolar disorder;Expert Review of Neurotherapeutics;2024-07-23

2. A Long-Term Safety and Tolerability Study of TV-46000 for Subcutaneous Use in Patients with Schizophrenia: A Phase 3, Randomized, Double-Blinded Clinical Trial;CNS Drugs;2024-07-02

3. An Open-Label Study to Assess Monthly Risperidone Injections (180 mg) Following Switch from Daily Oral Risperidone (6 mg) in Stable Schizophrenic Patients;Clinical Drug Investigation;2024-02-22

4. Efficacy and safety of TV-46000, a long-acting, subcutaneous, injectable formulation of risperidone, for schizophrenia: a randomised clinical trial in the USA and Bulgaria;The Lancet Psychiatry;2023-12

5. Long-Acting Injectable Antipsychotic Treatment for Schizophrenia in Asian Population: A Scoping Review;Neuropsychiatric Disease and Treatment;2023-09

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3